Kidney Disease & Nephrology Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS

This Phase 4 study from Nantes University Hospital explores a new way to stop eculizumab treatment safely in people with atypical hemolytic uremic syndrome (aHUS), a rare kidney condition. By using a special algorithm to guide when to stop the medication, the study hopes to reduce the need for ongoing treatment and lessen side effects. The results from 58 participants in France will help doctors decide how long patients might need eculizumab.

Sit Less, Interact and Move More (SLIMM) 2 Study

This Phase 2 trial in the United States is testing whether a mix of resistance training and the medication semaglutide can help people with chronic kidney disease and obesity move more and sit less. The goal is to improve muscle strength and overall health by encouraging physical activity. If successful, this approach could offer a new way to support kidney health by reducing sedentary behavior over a 12-month period.

Niaoduqing Granules in Older Adults With Impaired Kidney Function

Researchers in China are studying Niaoduqing Granules, an herbal oral treatment, in older adults with moderate to severe chronic kidney disease. This Phase 4 trial aims to find out if the granules can slow down the worsening of kidney function and improve health over up to five years. This could provide an additional treatment option alongside current care for older patients.

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

Johns Hopkins University is leading a study on the best timing to start antiviral medication for Hepatitis C in patients receiving kidney transplants from donors with HCV infection. By comparing treatment started before versus after transplant, this research hopes to improve the transplant process and reduce the overall duration of medication. The study is enrolling 120 participants in the United States.

Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria

This trial in China is testing whether combining finerenone and semaglutide can better protect the kidneys in adults with obesity and chronic kidney disease who do not have diabetes. The focus is on reducing albuminuria, a sign of kidney damage, more effectively than semaglutide alone. Around 266 participants will receive treatment for 24 weeks to assess safety and benefits.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.